Cohen MS - Search Results

1

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.

Kim A, Cohen MS. Kim A, et al. Among authors: cohen ms. Expert Opin Drug Discov. 2016 Sep;11(9):907-16. doi: 10.1080/17460441.2016.1201057. Epub 2016 Jun 23. Expert Opin Drug Discov. 2016. PMID: 27327499 Free PMC article. Review.

2

The discovery and development of vandetanib for the treatment of thyroid cancer.

Sim MW, Cohen MS. Sim MW, et al. Among authors: cohen ms. Expert Opin Drug Discov. 2014 Jan;9(1):105-14. doi: 10.1517/17460441.2014.866942. Epub 2013 Dec 4. Expert Opin Drug Discov. 2014. PMID: 24299515 Review.

3

The discovery and development of sorafenib for the treatment of thyroid cancer.

White PT, Cohen MS. White PT, et al. Among authors: cohen ms. Expert Opin Drug Discov. 2015 Apr;10(4):427-39. doi: 10.1517/17460441.2015.1006194. Epub 2015 Feb 8. Expert Opin Drug Discov. 2015. PMID: 25662396 Free PMC article. Review.

4

In reply: Management of thin melanoma.

Durham AB, Schwartz JL, Lowe L, Zhao L, Johnson AG, Harms KL, Bichakjian CK, Orsini AP, McLean SA, Bradford CR, Cohen MS, Johnson TM, Sabel MS, Wong SL. Durham AB, et al. Among authors: cohen ms. J Surg Oncol. 2018 Mar;117(3):536. doi: 10.1002/jso.24858. Epub 2017 Nov 11. J Surg Oncol. 2018. PMID: 29127705 Free article. No abstract available.

5

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.

Sanchez JN, Wang T, Cohen MS. Sanchez JN, et al. Among authors: cohen ms. Drugs. 2018 Apr;78(5):549-566. doi: 10.1007/s40265-018-0884-8. Drugs. 2018. PMID: 29488071 Free PMC article. Review.

6

Improved durable responses regardless of age following cytoreduction and "no-tourniquet" hyperthermic isolated limb chemotherapy for in transit melanoma of the extremity.

Wang T, Osborne N, Rechtenwald J, Kim A, Matusko N, Mayle R, Cohen MS. Wang T, et al. Among authors: cohen ms. Am J Surg. 2019 Dec;218(6):1114-1121. doi: 10.1016/j.amjsurg.2019.09.034. Epub 2019 Oct 5. Am J Surg. 2019. PMID: 31630826 Free PMC article.

7

Old and New Approaches to Target the Hsp90 Chaperone.

Sanchez J, Carter TR, Cohen MS, Blagg BSJ. Sanchez J, et al. Among authors: cohen ms. Curr Cancer Drug Targets. 2020;20(4):253-270. doi: 10.2174/1568009619666191202101330. Curr Cancer Drug Targets. 2020. PMID: 31793427 Free PMC article. Review.

8

The discovery and development of binimetinib for the treatment of melanoma.

Tran B, Cohen MS. Tran B, et al. Among authors: cohen ms. Expert Opin Drug Discov. 2020 Jul;15(7):745-754. doi: 10.1080/17460441.2020.1746265. Epub 2020 Apr 4. Expert Opin Drug Discov. 2020. PMID: 32249628 Free PMC article. Review.

9

A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas.

Sanchez JN, Subramanian C, Chanda M, Shanguan G, Zhang N, Wang T, Timmermann BN, Blagg BSJ, Cohen MS. Sanchez JN, et al. Among authors: cohen ms. Melanoma Res. 2021 Jun 1;31(3):197-207. doi: 10.1097/CMR.0000000000000734. Melanoma Res. 2021. PMID: 33904516 Free PMC article.

10

Advances in the discovery and development of melanoma drug therapies.

Chanda M, Cohen MS. Chanda M, et al. Among authors: cohen ms. Expert Opin Drug Discov. 2021 Nov;16(11):1319-1347. doi: 10.1080/17460441.2021.1942834. Epub 2021 Jul 19. Expert Opin Drug Discov. 2021. PMID: 34157926 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,379 results

Search Page

Filters